Further studies showed that the levels of ATP7B were inversely correlated with cisplatin sensitivity in nine gynecological cancer cell lines (see example in Figure 3) and that ovarian cancer patients with ATP7B expression had a significantly poorer response to cisplatin-based chemotherapy than patients lacking detectable ATP7B expression [104]. This evidence concerns the gene ATP7B and female reproductive organ cancer.